Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

MED25 Gene CMT2B2 Next-Generation Sequencing DNA Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين MED25 لاعتلال الأعصاب الوراثي CMT2B2 بتقنية التسلسل الجيني من الجيل التالي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

DHA Licensed Facility: 9834453 ISO 9001:2015 Certified (INT/EGQ/2509DA/3139) 2026 Federal Decree-Law No. 41 (Art. 87) Compliant

Executive Summary

  • ✔ 99.9% Diagnostic Sensitivity – ISO‑accredited NGS processing
  • ✔ Hospital‑grade home collection by ISO certified cold‑chain logistics & VIP mobile phlebotomy (8 AM–11 PM)
  • ✔ Post‑test telephonic clinical guidance included
  • ✔ Direct insurance billing verification via WhatsApp +971 54 548 8731

ملخص تنفيذي: يقدم هذا التحليل الجيني الشامل تحليل جين MED25 بدقة تشخيصية تصل إلى 99.9% وفقاً لمعايير الآيزو 9001:2015، مع خدمة سحب عينات منزلية معتمدة من هيئة الصحة بدبي. يتم إجراء التحليل في مختبر مرخص وبإشراف أطباء متخصصين، مع استشارة هاتفية بعد النتيجة. للحجز أو الاستفسار، تواصل عبر واتساب على الرقم 971545488731.

Test Overview

This advanced genetic test sequences the entire coding region of the MED25 gene to diagnose Charcot‑Marie‑Tooth disease type 2B2 (CMT2B2)—a progressive hereditary neuropathy—using next‑generation sequencing with unmatched precision.

هذا الاختبار الجيني المتطور يحلل جين MED25 لتشخيص مرض شاركو‑ماري‑توث من النوع 2B2 بدقة فائقة.

Feature Our MED25 NGS Test Closest UAE Alternative
Precision99.9% sensitivity, full gene coverageLimited panel, ~85% sensitivity
MethodologyNGS (Illumina platform, 2026 protocols)Sanger sequencing or older NGS
Turnaround3–4 Weeks6–8 Weeks
Price2800 AED (all‑inclusive)3500+ AED (often additional fees)
DHA/CDS ComplianceFull Federal Decree‑Law No. 41 of 2024 (Art. 87) & CDS 2026 (minors)Variable
Insurance BillingDirect WhatsApp verification +971 54 548 8731Manual claims

Physician Insight & Safety Protocol

“As a DHA‑licensed neurologist (DHA: 61713011), I emphasize that this MED25 genetic test reveals inherited risk for CMT2B2, but a definitive diagnosis requires correlation with your clinical neurological examination and detailed family history. Genetic counselling before and after testing is essential to interpret the findings accurately and understand implications for family members.” – Dr. Prabhakar Reddy

Medication Advisory

Do not discontinue any prescribed medication without consulting your treating physician. This test is for genetic risk assessment and does not replace ongoing neurological care or acute medical management.

Exclusion Criteria & Emergency Red Flags

  • Exclusion: Inability to provide informed consent; current anticoagulant therapy without physician clearance for blood draw; known severe needle phobia with no medical alternative.
  • Emergency Red Flags – Seek immediate medical attention if you experience: Sudden paralysis, respiratory distress, severe unrelenting pain, or rapid progression of muscle weakness. This genetic test is not an acute diagnostic tool.
  • For minors, 2026 UAE CDS Law requires a parent/legal guardian to accompany the child and provide written consent; a mandatory pre‑test genetic counselling session applies.

Patient FAQs & Clinical Guidance

What is the MED25 gene CMT2B2 Genetic Test used for?

This test sequences the MED25 gene to diagnose Charcot‑Marie‑Tooth disease type 2B2, a hereditary neuropathy causing progressive muscle weakness and sensory loss. It is intended for individuals with a clinical suspicion of CMT2B2, a family history of the condition, or carriers seeking reproductive planning. The result guides neurologists and genetic counsellors in tailoring surveillance and management.

يستخدم هذا الاختبار لتشخيص مرض شاركو‑ماري‑توث من النوع 2B2 عبر تحليل جين MED25، وهو موجه للمرضى الذين لديهم أعراض أو تاريخ عائلي للمرض.

How is the test performed and what is the sample requirement?

A blood sample, extracted DNA, or a single drop of blood on an FTA card is collected at home by our DHA‑licensed phlebotomist using cold‑chain logistics. The sample is then processed via NGS technology in our ISO‑certified laboratory. Pre‑test, a genetic counselling session is conducted to draw a pedigree chart and document any clinical history of CMT2B2.

يتم سحب عينة دم أو مسحة على بطاقة FTA بواسطة أخصائي معتمد من هيئة الصحة بدبي في المنزل، مع جلسة استشارة وراثية قبل الاختبار.

What is the turnaround time and cost in UAE, and is insurance accepted?

The test costs 2800 AED with results delivered within 3 to 4 weeks, including a telephonic post‑ consultation to explain the findings. We provide direct billing assistance; simply send your insurance card via WhatsApp to +971 54 548 8731 to verify coverage instantly. UAE PDPL ensures your genetic data is stored and shared only with your explicit consent.

تبلغ تكلفة الاختبار 2800 درهم، وتصدر النتائج خلال 3 إلى 4 أسابيع مع استشارة هاتفية توضيحية. يتوفر دعم مباشر للفوترة التأمينية عبر واتساب.

DHA Facility License: 9834453 | ISO 9001:2015 Certified (INT/EGQ/2509DA/3139) | UAE PDPL Compliant | Federal Decree‑Law No. 41 of 2024 (Art. 87) | CDS 2026 (Minors)

Home collection available daily 8 AM – 11 PM. For appointments or billing verification, WhatsApp: +971 54 548 8731

Diagnostic methodology: NGS (Illumina), LOINC 96646-0 – Hereditary neuropathy multigene panel. ICD‑10: G60.0, Z13.71, Z84.81

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians